Modeling and Simulation - PK/PD Archives | Page 30 of 43

On-Demand Webinar

Phoenix WinNonlin: A State of the Art Software Tool for Pre-clinical PK and TK Analysis

Are you currently using Excel for PK/TK analysis? Phoenix WinNonlin streamlines analyses and generates all…

CertaraNovember 21, 2013

Knowledge Base

What is Identifiability?

Developing models for pharmacokinetic or pharmacodynamic data requires creativity, patience, and hard work. Sometimes that…

CertaraNovember 18, 2013

On-Demand Webinar

Introduction to Population PK/PD Analysis Using Phoenix NLME

Phoenix NLME provides sophisticated algorithms and powerful and flexible data processing and modeling tools for…

CertaraNovember 14, 2013

Publication

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

The aim of this study was to assess the cardiovascular effects of a new inhaled…

CertaraNovember 1, 2013

Knowledge Base

What is the -2LL or the Log-likelihood Ratio?

Understand the 2LL (Log-likelihood Ratio) and its role in statistical analysis. Explore how it aids…

CertaraOctober 28, 2013

Publication

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Categorizations of best response observed at week 8 of first-line treatment in two studies of…

CertaraOctober 22, 2013

Knowledge Base

Using Sampling “Windows” for PK Blood Samples

One of the most common questions posed by clinical operations experts when including pharmacokinetic sampling…

CertaraOctober 15, 2013

Publication

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

CertaraOctober 10, 2013

Publication

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

CertaraOctober 1, 2013

Publication

Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers

Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor…

CertaraOctober 1, 2013

Modeling and Simulation – PK/PD

Phoenix WinNonlin: A State of the Art Software Tool for Pre-clinical PK and TK Analysis

What is Identifiability?

Introduction to Population PK/PD Analysis Using Phoenix NLME

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

What is the -2LL or the Log-likelihood Ratio?

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Using Sampling “Windows” for PK Blood Samples

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers

Newsletter sign up

Quick links

Solutions

Contact